Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. - Wikidata - awgldk - TriplyDB

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

http://www.wikidata.org/entity/Q34278437

about

Acute lymphoblastic leukaemia Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future Recent advancements of bortezomib in acute lymphocytic leukemia treatment Recent advances and novel treatment paradigms in acute lymphocytic leukemia From bench to bedside: lessons learned in translating preclinical studies in cancer drug development The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment.Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group Challenges of clinical trial design for targeted agents against pediatric leukemias.Novel agents for the treatment of childhood acute leukemia.Improving access to novel agents for childhood leukemia.Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.Molecular profiling of childhood cancer: Biomarkers and novel therapies Advances in paediatric cancer treatment Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia A 50-year journey to cure childhood acute lymphoblastic leukemia Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.Proteasome inhibitors in acute leukemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Novel targeted therapies in acute lymphoblastic leukemia.Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.Novel approaches to pediatric leukemia treatment.Natural compounds for pediatric cancer treatment.Adolescent and young adult non-Hodgkin lymphoma.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.The role of bortezomib in the treatment of acute lymphoblastic leukemia.

P2860

Q24602387-E9FF9CFC-5ADD-482D-8DC3-189B97EA03EF Q26746934-79EF05D3-5DC7-4864-B46D-49E61B97F102 Q26829613-35B77C34-C836-4B8B-A0E8-BB1B43727B22 Q28078076-78D28A7F-EAE0-4974-8D95-394BEAB93D36 Q28533949-73E5CDB0-D04D-4A44-ABAD-E391E0D4903D Q30248842-AC34E7F9-AE57-4F20-8879-C740FEB90099 Q30252776-B671E2C5-2D4D-4A16-91C2-38C0D3F9A6AA Q33414592-92A49B95-3015-4F28-B65F-157BEDF7F2B7 Q33416169-55FB968F-B434-49B5-BE8F-B12AEC0E3BB3 Q33694514-3AA39388-F45B-4044-BAAB-33EB8AADB4BE Q33711119-78AF6393-1D85-449F-B169-B172171059E9 Q33742779-A01B40E1-EB0F-479E-AAF8-7E628F1195C5 Q33828073-526B01B9-FA81-4AD2-BC07-8D46DFFAD131 Q34585047-AE551EBD-0D2F-4588-A83F-429EDBB8B4CB Q34839887-143EDB92-C103-45B0-98B2-154A698AE902 Q35192790-7E206D34-CBD7-4A05-BBB4-7B05EF6F6F7B Q35688742-FBB8E083-7F46-4FBD-9DD3-65F15639EAE5 Q35957567-E5A7D846-CB48-40D0-A843-E4B83049C364 Q36176588-16A7D0B1-3526-42EF-A10A-2EDB0EC18B4C Q36250783-922480BB-F9B6-479B-8D9B-4BC32E34A952 Q36508630-EC3A6010-621B-4E4F-ACFF-FE6ADDBBEA92 Q36545969-889F8A1E-1054-4130-B1FF-4F20D970257F Q36738818-EE3EA2EE-09B7-4709-975B-5D9725BB942B Q36955757-DA8094A8-9916-4F2F-A9AD-22D781FA9C15 Q37166753-D4F2311C-AFC4-495E-9503-ADF3DB7B9028 Q37233146-B6587E2C-C6E1-4314-8000-1C89B7F594EE Q37377911-2E69147B-8DE6-439C-B685-36D2BC3B287A Q37643136-7C99D63E-8EC2-4FF2-900C-8B3348FA98D9 Q37723478-B74241C5-EB8D-4DE4-954B-FE0B1B89C21A Q38033592-C54CA2DE-487F-4196-B035-ED9F28378FF2 Q38088003-11839EE5-C998-4BF5-8FFD-416689A51968 Q38097334-47C831EB-07E2-4201-88F4-17E5D55F615C Q38120551-87B54E6F-749A-4C4A-B4C0-7D8E9C897687 Q38164108-75FF551A-2B51-4ECE-BF3B-18E9897ABE2D Q38282458-CC294EF7-8DFE-4B90-9F34-AD2BB15DED04 Q38500371-042F7535-2EB8-4538-950A-BEBDEE102AF0 Q38663897-E244EB4B-9AD2-4DF6-AC4E-63F052D72F19 Q38806478-B01AC26B-C99D-4BA0-9C1C-05282A6D4FD0 Q38813978-FC8548B5-B090-464E-8530-263BD39708D9 Q38833230-E878EFFF-85CC-4CAF-849D-5F5CA9D5728F

P2860

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

http://www.wikidata.org/entity/Q34278437

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.

@ast

Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.

@en

Bortezomib with chemotherapy i ...... Childhood Leukemia & Lymphoma

@nl

type

label

Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.

@ast

Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.

@en

Bortezomib with chemotherapy i ...... Childhood Leukemia & Lymphoma

@nl

prefLabel

Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.

@ast

Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.

@en

Bortezomib with chemotherapy i ...... Childhood Leukemia & Lymphoma

@nl

P1433

Q34278437-65621613-D81A-4FB4-B068-595F4FFD5291

P1476

Q34278437-45455BF8-CA89-4486-84AA-4EA2A6F95AAF

P2093

Q34278437-07B8943A-0EE0-4FB6-B629-00E96B4F2996

Q34278437-213E778F-07A6-4711-9D41-A0DC7553DB6D

Q34278437-77EFB938-C045-4E6F-A7C3-F0BFDEE65591

Q34278437-A3929B67-480A-4ADD-A27C-879873DDDEB2

Q34278437-AF403AFB-6E2F-470C-971F-948145748B4E

Q34278437-B232C7A9-24BF-47A9-821B-BF65D3C80F11

Q34278437-CD53037C-77B6-4209-AB3A-6993F122797F

P304

Q34278437-81847B04-9CD7-4DF4-A5AC-46B9CC1084EE

P31

Q34278437-272B7180-5972-4C5C-AF3E-9710323D01BA

P356

Q34278437-92F173A8-DC05-4ABD-810D-6E238908F9C9

P407

Q34278437-33CE56EB-A20A-4EA4-9B25-71BBABE52332

P433

Q34278437-28A73403-EF16-47D4-831D-DF1F1A500E4F

P478

Q34278437-47E5ECA2-CB27-48AA-AE06-2C3924E94355

P50

Q34278437-A2697564-516B-442A-A3DA-C6ABA94A0BA2

P577

Q34278437-6D934C85-426A-4668-9F0C-DD469B0082A3

P5875

Q34278437-854EF033-0316-4155-BAC4-4D775EED5084

P698

Q34278437-8D7B81B1-7035-48E2-94A6-3A8A59E330E0

P921

Q34278437-2B27497A-F3D8-4F59-ABFF-EFA9D0B469AA

Q34278437-51EFF0A3-AA5D-4584-B64B-C17052713E19

P356

BLOOD-2012-04-418640

P1433

P1476

Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.

@en

P2093

Bruce C Bostrom

http://www.w3.org/2001/XMLSchema#string

Elena Eckroth

http://www.w3.org/2001/XMLSchema#string

Jeannette van der Giessen

http://www.w3.org/2001/XMLSchema#string

Jemily Malvar

http://www.w3.org/2001/XMLSchema#string

Richard Sposto

http://www.w3.org/2001/XMLSchema#string

Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

http://www.w3.org/2001/XMLSchema#string

Yoav H Messinger

http://www.w3.org/2001/XMLSchema#string

P304

285-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-04-418640

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225088525

http://www.w3.org/2001/XMLSchema#string

P698

22653976

http://www.w3.org/2001/XMLSchema#string

P921